Opioid Use Disorder (OUD) Market Size, Share, and Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, Sublingual, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
Opioid Use Disorder (OUD) Market Size, Share, and Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, Sublingual, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
PRODUCT OVERVIEW
Opioid Use Disorder (OUD) Market is anticipated t%li%grow at a CAGR of 10% in the forecast period (2024-2034), with the market size valued at USD 3.3 billion in 2023 and projected t%li%reach USD 9.5 billion by 2034.
Opioid Use Disorder (OUD) is a chronic medical illness that involves a problematic pattern of opioid usage and causes substantial pain or suffering. Those with opioid use disorder usually display an uncontrollable need t%li%use opioids despite severe effects, such as health challenges and interpersonal issues. This disorder can emerge from various sources, such as the misuse of prescription opioids, along with illicit drug usage or even medically supervised opioid treatment. In addition, opioid use disorder can involve serious symptoms such as extreme cravings, withdrawal symptoms after stopping, and an inability t%li%control consumption. Furthermore, treatment for OUD involves an integrated approach, such as medication and therapy, t%li%ensure long-term recovery. Therefore, timely intervention and extensive support are crucial for tackling this complicated and demanding illness.
MARKET HIGHLIGHTS
Opioid Use Disorder (OUD) Market is anticipated t%li%reach USD 9.5 billion, growing at a CAGR of 10% during the forecast period, due t%li%increasing awareness and proactive governmental efforts t%li%address the opioid crisis. The expansion of the opioid use disorder market is attributed t%li%the rising prevalence of OUD and the development of modern therapies t%li%meet the evolving needs of patients. In addition, major industry players are investing in the creation of new medications and therapies, such as long-acting formulations and non-opioid alternatives. Moreover, while specific regions may have different approaches for the prevention and treatment of opioid misuse, collaboration among stakeholders remains crucial for the industry. This collaborative effort ensures constant innovation in the opioid use disorder market, which ultimately contributes t%li%the goal of reducing the impact of opioid addiction on public health.
Opioid Use Disorder Market Segments:
Growth Drivers
Growing Awareness and Treatment Options t%li%Expand the Market
Innovations in Technology and Treatment Will Positively Influence the Market
Restraint
Legal and Regulatory Restrictions are a Significant Challenge t%li%Market Growth
Key Players
PRODUCT OVERVIEW
Opioid Use Disorder (OUD) Market is anticipated t%li%grow at a CAGR of 10% in the forecast period (2024-2034), with the market size valued at USD 3.3 billion in 2023 and projected t%li%reach USD 9.5 billion by 2034.
Opioid Use Disorder (OUD) is a chronic medical illness that involves a problematic pattern of opioid usage and causes substantial pain or suffering. Those with opioid use disorder usually display an uncontrollable need t%li%use opioids despite severe effects, such as health challenges and interpersonal issues. This disorder can emerge from various sources, such as the misuse of prescription opioids, along with illicit drug usage or even medically supervised opioid treatment. In addition, opioid use disorder can involve serious symptoms such as extreme cravings, withdrawal symptoms after stopping, and an inability t%li%control consumption. Furthermore, treatment for OUD involves an integrated approach, such as medication and therapy, t%li%ensure long-term recovery. Therefore, timely intervention and extensive support are crucial for tackling this complicated and demanding illness.
MARKET HIGHLIGHTS
Opioid Use Disorder (OUD) Market is anticipated t%li%reach USD 9.5 billion, growing at a CAGR of 10% during the forecast period, due t%li%increasing awareness and proactive governmental efforts t%li%address the opioid crisis. The expansion of the opioid use disorder market is attributed t%li%the rising prevalence of OUD and the development of modern therapies t%li%meet the evolving needs of patients. In addition, major industry players are investing in the creation of new medications and therapies, such as long-acting formulations and non-opioid alternatives. Moreover, while specific regions may have different approaches for the prevention and treatment of opioid misuse, collaboration among stakeholders remains crucial for the industry. This collaborative effort ensures constant innovation in the opioid use disorder market, which ultimately contributes t%li%the goal of reducing the impact of opioid addiction on public health.
Opioid Use Disorder Market Segments:
- By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
- By Route of Administration
- Oral
- Sublingual
- Intravenous
- By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Growth Drivers
Growing Awareness and Treatment Options t%li%Expand the Market
Innovations in Technology and Treatment Will Positively Influence the Market
Restraint
Legal and Regulatory Restrictions are a Significant Challenge t%li%Market Growth
Key Players
- Reckitt Benckiser Pharmaceuticals
- Johnson & Johnson
- Purdue Pharma
- Teva Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Indivior
- Pfizer Inc.
- GlaxoSmithKline plc
- Alkermes plc
- Titan Pharmaceuticals
- Camurus AB
- BioDelivery Sciences International, Inc.
- Braeburn Inc.
- Orex%li%AB
- Insys Therapeutics
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected t%li%witness the fastest growth as well as t%li%dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect t%li%recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight int%li%the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years t%li%come
- 3-month post-sales analyst support.
1. EXECUTIVE SUMMARY
1.1.Regional Market Share
1.2. Business Trends
1.3.Opioid Use Disorder (OUD) Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1. Market Definition
3.2.Opioid Use Disorder (OUD) Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. OPIOID USE DISORDER (OUD) MARKET – INDUSTRY INSIGHTS
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7.MARKET DYNAMICS
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. RISK ANALYSIS
9. MARKET ANALYSIS
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. OPIOID USE DISORDER (OUD) MARKET
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Drug Class
11.3.1.1. Buprenorphine
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Methadone
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Naltrexone
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Oral
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Sublingual
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Intravenous
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2.Market Share (%) 2024-2034F
11.3.2.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3. By Distribution Channels
11.3.3.1.Hospitals Pharmacies
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Retail Pharmacies
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Online Pharmacies
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
12. NORTH AMERICA OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Class
12.3.2.By Route of Administration
12.3.3.By Distribution Channels
12.4. Country
12.4.1. United States
12.4.2.Canada
13. EUROPE OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Class
13.3.2.By Route of Administration
13.3.3.By Distribution Channels
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. ASIA-PACIFIC OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Class
14.3.2.By Route of Administration
14.3.3.By Distribution Channels
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. MIDDLE EAST AND AFRICA OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Class
15.3.2.By Route of Administration
15.3.3.By Distribution Channels
15.4. Country
15.4.1. Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4. South Africa
15.4.5.Rest of Middle East and Africa
16. LATIN AMERICA OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Class
16.3.2.By Route of Administration
16.3.3.By Distribution Channels
16.4. Country
16.4.1. Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1. Reckitt Benckiser Pharmaceuticals
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.Johnson & Johnson
18.3.Purdue Pharma
18.4.Teva Pharmaceuticals
18.5.Mallinckrodt Pharmaceuticals
18.6.Indivior
18.7.Pfizer Inc.
18.8.GlaxoSmithKline plc
18.9.Alkermes plc
18.10.Titan Pharmaceuticals
18.11. Camurus AB
18.12.BioDelivery Sciences International, Inc.
18.13.Braeburn Inc.
18.14.Orexo AB
18.15.Insys Therapeutics
18.16.Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
1.1.Regional Market Share
1.2. Business Trends
1.3.Opioid Use Disorder (OUD) Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1. Market Definition
3.2.Opioid Use Disorder (OUD) Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. OPIOID USE DISORDER (OUD) MARKET – INDUSTRY INSIGHTS
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7.MARKET DYNAMICS
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. RISK ANALYSIS
9. MARKET ANALYSIS
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. OPIOID USE DISORDER (OUD) MARKET
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Drug Class
11.3.1.1. Buprenorphine
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Methadone
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Naltrexone
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Oral
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Sublingual
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Intravenous
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2.Market Share (%) 2024-2034F
11.3.2.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3. By Distribution Channels
11.3.3.1.Hospitals Pharmacies
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Retail Pharmacies
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Online Pharmacies
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
12. NORTH AMERICA OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Class
12.3.2.By Route of Administration
12.3.3.By Distribution Channels
12.4. Country
12.4.1. United States
12.4.2.Canada
13. EUROPE OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Class
13.3.2.By Route of Administration
13.3.3.By Distribution Channels
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. ASIA-PACIFIC OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Class
14.3.2.By Route of Administration
14.3.3.By Distribution Channels
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. MIDDLE EAST AND AFRICA OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Class
15.3.2.By Route of Administration
15.3.3.By Distribution Channels
15.4. Country
15.4.1. Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4. South Africa
15.4.5.Rest of Middle East and Africa
16. LATIN AMERICA OPIOID USE DISORDER (OUD) MARKET SIZE & FORECAST 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Class
16.3.2.By Route of Administration
16.3.3.By Distribution Channels
16.4. Country
16.4.1. Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1. Reckitt Benckiser Pharmaceuticals
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.Johnson & Johnson
18.3.Purdue Pharma
18.4.Teva Pharmaceuticals
18.5.Mallinckrodt Pharmaceuticals
18.6.Indivior
18.7.Pfizer Inc.
18.8.GlaxoSmithKline plc
18.9.Alkermes plc
18.10.Titan Pharmaceuticals
18.11. Camurus AB
18.12.BioDelivery Sciences International, Inc.
18.13.Braeburn Inc.
18.14.Orexo AB
18.15.Insys Therapeutics
18.16.Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
